FDA approves GSK's JAK inhibitor for rare blood cancer after three-month delay

Lei Lei Wu

News Reporter

The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves GSK's JAK inhibitor for rare blood cancer after three-month delay

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA approves GSK's JAK inhibitor for rare blood cancer after three-month delay